Sunflower Pharmaceutical transfers two investments on same day, refocuses on core business after first loss in 11 years as listed company

EarningsCorporate Action
โดย 读创财经·Read original
Summary · why it matters

Sunflower Pharmaceutical announced the transfer of two investments on the same day. It sold a 10.3896 percent stake in Beijing Famaxing Pharmaceutical Technology Company to Guangzhou Baiyunshan Heji Gong Pharmaceutical Company for 34.285768 million yuan, and transferred its 1 million yuan capital contribution in Hangzhou Xiaochi Feihong Venture Capital Partnership to natural person Wu Mingxing for 1 million yuan. After the transactions, the company no longer holds any equity in the two entities. The company said the move aims to focus on its core business track of "the elderly, children, and women" and optimize its investment structure. In 2025, the company's full-year revenue was 2.318 billion yuan, down 31.36 percent year-on-year, and net profit attributable to the parent was negative 258 million yuan, down 152.40 percent year-on-year, marking the first operating loss in the company's 27-year history and 11 years as a listed company. Over the same period, selling expenses reached 580 million yuan, up 34.60 percent year-on-year, while research and development spending was 111 million yuan, down 10.49 percent year-on-year. In the first quarter of this year, the company achieved revenue of 844 million yuan, up 27.19 percent year-on-year, and net profit attributable to the parent of 110 million yuan, up 93.11 percent year-on-year.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 2

北京法玛星医药科技有限公司Private▼ Negative
Capitalrelevance

Sunflower Pharmaceutical sold its stake in Beijing Famaxing, indicating a divestment.

广州白云山何济公药业有限公司Private▲ Positive
Capitalrelevance

Guangzhou Baiyunshan Heji Gong acquired a stake in Beijing Famaxing from Sunflower Pharmaceutical.

© 2026 MarketDXNews